Last updated on April 2019

A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors


Brief description of study

A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

Detailed Study Description

This is an open-label, multicenter, Phase 1b platform study in subjects with advanced or metastatic solid tumors (Part 1a) and subjects with selected solid tumors (Part 1b and Part 2).

Two treatment groups (Group A and Group B) will be evaluated.

Part 1a utilizes a 3+3 design to evaluate pembrolizumab and INCB combinations in advanced solid tumors. 

  • Group A will evaluate a JAK inhibitor with JAK1 selectivity itacitinib (INCB039110) in combination with pembrolizumab (MK-3475) and
  • Group B will evaluate a PI3K-delta inhibitor (INCB050465) in combination with pembrolizumab to determine the maximum0 tolerated dose (MTD) or PAD and recommend a dose for the Part 1b safety expansion with each combination.

Once the recommended dose has been identified in Part 1a, subjects with select solid tumor types will be enrolled into safety expansion cohorts based upon prior treatment history with a PD-1 pathway-targeted agent (Part 1b) for each combination. 

Part 2 utilizes a Simon 2-Stage design to evaluate INCB050465 in combination with pembrolizumab in patients with small cell lung cancer (SCLC) and a 1 stage design to evaluate the combination in patients with non-small cell lung cancer (NSCLC) and urothelial cancer (UC).

 

Clinical Study Identifier: TX144824

Find a site near you

Start Over

Dana Farber Cancer Institute

Located in: Boston, MA USA
  Connect »

Duke Cancer Institute

Located in: Durham, NC USA
  Connect »

Karmanos Cancer Center

Located in: Detroit, MI USA
  Connect »

Henry Ford Hospital System

Located in: Detroit, MI USA
  Connect »

Utah Cancer Specialists

Located in: Salt Lake City, UT USA
  Connect »

St. Luke's Hospital of Kansas City

Located in: Kansas City, MO USA
  Connect »

University of Kentucky, Markey Cancer Center

Located in: Lexington, KY United States
  Connect »